NuVasive: Outpacing a Slowing Spine Market

For the past several years, NuVasive has been growing faster than its rivals in spine, thanks to its innovative XLIF procedure, a lateral approach to minimally-invasive spine surgery. But now the spine market overall has hit a wall. In a market no longer growing, can NuVasive continue to grow?

For much of the past decade, the spinal device market has, in competitive terms, been characterized by two dynamics: first, a rapidly expanding market driven at least in part by a host of new technologies produced by an equally large number of new companies, many of them venture-backed start-ups, and second, a continued dominance, at least in terms of market share, by the industry leaders, most notably Medtronic Sofamor Danek USA Inc. (MSD), a unit of Medtronic PLC, a dominance all the more remarkable considering the volatility that a fast-growing, technology-rich market usually brings.

The long-standing market dominance of the industry leaders did little to dampen the spirits of the companies who were creating...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By 

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

BioBytes: AI-Related Deals In Q2 ‘25

 
• By 

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.